Novartis Needs A Bigger Safety Database For Menveo, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Review of application for ages 11 and up proceeds, but the agency wants to see more data on infants, pushing a second filing for the meningitis vaccine to 2011 in the U.S.